Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …

Immune checkpoint therapy has achieved significant efficacy by blocking inhibitory
pathways to release the function of T lymphocytes. In the clinic, anti-programmed cell death …

Background The role of tumor mutational burden (TMB) is still debated for selecting
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …

Summary Background Anti-PD-1 and PD-L1 antibodies (mAbs) are approved
immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only …

Checkpoint proteins are an integral part of the immune system and are used by the tumor
cells to evade immune response, which helps them grow uncontrollably. By blocking these …

Quantifying the effectiveness of different cancer therapies in patients with specific tumor
mutations is critical for improving patient outcomes and advancing precision medicine. Here …

Immunotherapy has been one of the great advances in the recent years for the treatment of
advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that …

Lung cancer is one of the most common cancers and the leading cause of cancer-related
deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present …

Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4
(CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal …